Evidence map›Paper›PMID 34918781›Full record

ArticleMovement disorders : official journal of the Movement Disorder Society2022

Mild Chronic Colitis Triggers Parkinsonism in LRRK2 Mutant Mice Through Activating TNF-α Pathway.

Chin-Hsien Lin, Han-Yi Lin, En-Pong Ho, Yi-Ci Ke, Mei-Fang Cheng, Chyng-Yann Shiue, Chi-Han Wu, Peng-Hsiang Liao, Angela Yu-Huey Hsu, Li-An Chu and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Movement disorders : official journal of the Movement Disorder Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 54 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. LRRK2NPJ Parkinson's disease · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. The interrelationship between intestinal immune cells and enteric α-synuclein in the progression of Parkinson's disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Exploring the relationship betweenFrontiers in neuroscience · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Chin-Hsien LinDepartment of Neurology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.ORCID 0000-0001-8566-7573
Han-Yi LinDepartment of Neurology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.
En-Pong HoDepartment of Neurology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.
Yi-Ci KeDepartment of Neurology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.
Mei-Fang ChengDepartment of Nuclear Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.
Chyng-Yann ShiueDepartment of Nuclear Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.
Chi-Han WuDepartment of Nuclear Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.
Peng-Hsiang LiaoCollege of Medicine, National Taiwan University, Taipei, Taiwan.ORCID 0000-0002-6104-220X
Angela Yu-Huey HsuCollege of Medicine, National Taiwan University, Taipei, Taiwan.
Li-An ChuDepartment of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu, Taiwan.
Ya-Ding LiuDepartment of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu, Taiwan.
Ya-Hui LinDepartment of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu, Taiwan.
Yi-Cheng TaiDepartment of Neurology, E-Da Hospital, Kaohsiung, Taiwan.
Chia-Tung ShunDepartment of Pathology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.
Han-Mo ChiuDepartment of Integrated Diagnostics and Therapeutics, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.
Ming-Shiang WuDepartment of Internal Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.
National Taiwan University Hospital · TWNational Tsing Hua University · TWNational Taiwan University · TWE-Da Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLeucine-rich repeat kinase 2 (LRRK2) is a common risk gene for Parkinson's disease (PD) and inflammatory bowel disorders. However, the penetrance of the most prevalent LRRK2 mutation, G2019S, is <50%. Factors other than genetic mutations are needed in PD process.

objectivesTo examine whether and how gut inflammation may act as an environmental trigger to neurodegeneration in PD.

methodsA mild and chronic dextran sodium sulfate (DSS)-induced colitis mice model harboring LRRK2 G2019S mutation was established. The colitis severity, immune responses, locomotor function, dopaminergic neuron, and microglia integrity were compared between littermate controls, transgenic LRRK2 wild type (WT), and LRRK2 G2019S mice.

resultsThe LRRK2 G2019S mice are more vulnerable to DSS-induced colitis than littermate controls or LRRK2 WT animals with increased intestinal expressions of pattern-recognition receptors, including toll-like receptors (TLRs), nuclear factor (NF)-κB activation, and pro-inflammatory cytokines secretion, especially tumor necrosis factor (TNF)-α. Notably, the colonic expression of α-synuclein was significantly increased in LRRK2 G2019S colitis mice. We subsequently observed more aggravated locomotor defect, microglia activation, and dopaminergic neuron loss in LRRK2 G2019S colitis mice than control animals. Treatment with anti-TNF-α monoclonal antibody, adalimumab, abrogated both gut and neuroinflammation, mitigated neurodegeneration, and improved locomotor function in LRRK2 G2019S colitis mice. Finally, we validated increased colonic expressions of LRRK2, TLRs, and NF-κB pathway proteins and elevated plasma TNF-α level in PD patients compared to controls, especially in those with LRRK2 risk variants.

conclusionsOur findings demonstrate that chronic colitis promotes parkinsonism in genetically susceptible mice and TNF-α plays a detrimental role in the gut-brain axis of PD. © 2021 International Parkinson and Movement Disorder Society.

Indexed as

ColitisParkinson DiseaseParkinsonian DisordersAnimalsAnimals, Genetically ModifiedHumansLeucine-Rich Repeat Serine-Threonine Protein Kinase-2MiceMice, TransgenicMutationTumor Necrosis Factor-alphaTumor Necrosis Factor InhibitorsLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, humanLrrk2 protein, mouseTumor Necrosis Factor-alphaTumor Necrosis Factor InhibitorsParkinson's diseasegut inflammationinflammatory bowel diseasegut-brain axisleucine-rich repeat kinase 2tumor necrosis factor-alpha

Identifiers

PMID34918781
OpenAlexW4200115285

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.